Singulair en es it fr

Categoria

Singulair Nombres de marca, Singulair Analogos

Singulair Marca los nombres de mezcla

  • No information avaliable
  • Singulair Formula quimica

    C35H36ClNO3S

    Singulair RX enlace

    http://www.rxlist.com/cgi/generic3/monteluk.htm

    Singulair FDA hoja

    Singulair FDA

    Singulair MSDS (hoja de seguridad de materiales)

    Singulair Sintesis de referencia

    ML Belley et al., Eur. Pat. Appl. 480,717 (1992)

    Singulair Peso molecular

    586.184 g/mol

    Singulair Punto de fusion

    No information avaliable

    Singulair H2O Solubilidad

    No hay información disponible

    Singulair Estado

    Solid

    Singulair LogP

    8.488

    Singulair Formas de dosificacion

    Tablet (oral)

    Singulair Indicacion

    Para el tratamiento del asma

    Singulair Farmacologia

    Montelukast, zafirlukast como, es un antagonista del receptor de leucotrienos utilizado como una alternativa a los medicamentos anti-inflamatorios en la gestión y el tratamiento crónico del asma y broncoespasmo inducido por el ejercicio (BEI). A diferencia de zafirlukast, montelukast no inhibe CYP2C9 o CYP3A4 y, por tanto, no espera que afecte a la eliminación hepática de los fármacos metabolizados por estas enzimas.

    Singulair Absorcion

    Absorbe rápidamente tras la administración oral (biodisponibilidad es del 64%)

    Singulair Toxicidad

    Los efectos secundarios incluyen dolor de cabeza, dolor abdominal o estomacal, tos, dolor dental, mareos, fiebre, ardor de estómago, erupciones en la piel, congestión nasal, debilidad o cansancio inusual.

    Singulair Informacion de Pacientes

    General

    • Patients should be advised to take montelukast daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physicians if their asthma is not well controlled.
    • Patients should be advised that oral tablets of montelukast are not for the treatment of acute asthma attacks. They should have appropriate short-acting inhaled b-agonist medication available to treat asthma exacerbations.
    • Patients should be advised that, while using montelukast, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for 24-hour period are needed.
    • Patients receiving montelukast should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
    • Patients who have exacerbations of asthma after exercise should be instructed to continue to use their usual regimen of inhaled b-agonists as prophylaxis unless otherwise instructed by their physician. All patients should have available for rescue a short-acting inhaled b-agonist.
    • Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast.
    Chewable Tablets:

    Phenylketonurics: Phenylketonuric patients should be informed that the chewable tablet contains phenylalanine (a component of aspartame) 0.842 mg per 5-mg chewable tablet.

    Singulair Organismos afectados

    Humanos y otros mamíferos